Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Type D personality, a joint tendency toward negative affectivity and social inhibition, has been linked to adverse events in patients with heart disease, although with inconsistent findings. Here, we apply an individual patient-data meta-analysis to data from 19 prospective cohort studies ( N = 11,151) to investigate the prediction of adverse outcomes by type D personality in patients with acquired cardiovascular disease.
Method: For each outcome (all-cause mortality, cardiac mortality, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, major adverse cardiac event, any adverse event), we estimated type D's prognostic influence and the moderation by age, sex, and disease type.
Results: In patients with cardiovascular disease, evidence for a type D effect in terms of the Bayes factor (BF) was strong for major adverse cardiac event (BF = 42.5; odds ratio [OR] = 1.14) and any adverse event (BF = 129.4; OR = 1.15). Evidence for the null hypothesis was found for all-cause mortality (BF = 45.9; OR = 1.03), cardiac mortality (BF = 23.7; OR = 0.99), and myocardial infarction (BF = 16.9; OR = 1.12), suggesting that type D had no effect on these outcomes. This evidence was similar in the subset of patients with coronary artery disease (CAD), but inconclusive for patients with heart failure (HF). Positive effects were found for negative affectivity on cardiac and all-cause mortality, with the latter being more pronounced in male than female patients.
Conclusion: Across 19 prospective cohort studies, type D predicts adverse events in patients with CAD, whereas evidence in patients with HF was inconclusive. In both patients with CAD and HF, we found evidence for a null effect of type D on cardiac and all-cause mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PSY.0000000000001164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse Childhood Experiences, Neurocognitive Functions, and Long-Term Mortality Risk.
JAMA Netw Open
September 2025
Social and Behavioral Sciences Branch, Division of Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
Importance: Higher intellectual abilities have been associated with lower mortality risk in several longitudinal cohort studies. However, these studies did not fully account for early life contextual factors or test whether the beneficial associations between higher neurocognitive functioning and mortality extend to children exposed to early adversity.
Objective: To explore how the associations of child neurocognition with mortality changed according to the patterns of adversity children experienced.
A review of the effect of SGLT2 inhibitors on clinical and glycemic outcomes in hospitalized patients: data from studies that included patients with diabetes.
Hormones (Athens)
September 2025
Division of Endocrinology, Baltimore VA Medical Center, Baltimore, MD, USA.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a fairly new class of agents for diabetes that have demonstrated significant benefits in glycemic control and cardiovascular outcomes with outpatient use. The aim of this review is to provide an overview of the effect of SGLT2i use on glycemic control and clinical outcomes in the hospital setting.An electronic search of PubMed was conducted to analyze publications that assessed the inpatient use of SGLT2i and included patients with diabetes.
View Article and Find Full Text PDFLosses to Follow-Up in a Nationally Representative Study of Community-Living Older Americans: Two Approaches to Censoring and Implications for Mortality Outcomes.
J Am Geriatr Soc
September 2025
Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA.
Background: In the National Health and Aging Trends Study (NHATS), use of its Sensitive files leads to incomplete ascertainment of mortality, largely because of losses to follow-up. To account for these losses, we compared two censoring approaches for evaluating mortality.
Methods: In a hybrid approach, most participants were censored at the time of last contact, while the remainder were censored at the time of last completed interview.
Cancer treatment delay and 5-year mortality among patients diagnosed with common cancers from 2000 to 2017 in the Philippines.
Jpn J Clin Oncol
September 2025
International Health Program, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong St., Beitou Dist., Taipei City 112, Taipei, Taiwan.
Objectives: Treatment delay can adversely affect cancer prognosis and public health. However, previous studies have not examined the association between cancer treatment delay and 5-year mortality risk for various cancer types in a single study population.
Methods: We used retrospective cohort data from 21 740 patients diagnosed with common cancers between 2000 and 2017, with mortality follow-up to 2022, from the Philippines' Department of Health-Rizal Cancer Registry to understand how treatment delay of <30, 30-90, or >90 days was associated with 5-year all-cause mortality risk, by cancer type and stage at diagnosis.
Comparison of short- and long-term outcomes between transcatheter and surgical aortic valve replacement for bicuspid aortic valve stenosis: a systematic review and meta-analysis.
Int J Surg
September 2025
Department of Cardiovascular Surgery, The Affiliated Hospital, Southwest Medical University, Metabolic Vascular Diseases Key Laboratory of Sichuan Province, Key Laboratory of Cardiovascular Remodeling and Dysfunction, Luzhou, Sichuan, PR China.
Objective: This meta-analysis aimed to compare the perioperative safety and efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in bicuspid aortic valve (BAV) stenosis.
Methods: We systematically analyzed studies from PubMed, Cochrane Library, Embase, and CNKI comparing TAVR and SAVR in BAV stenosis. Outcomes included postoperative mortality, complications, all-cause survival, and freedom from stroke.